Nonopioid Analgesia After Labral Surgery

NCT ID: NCT03825809

Last Updated: 2019-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-22

Study Completion Date

2020-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, single blinded, standard of care controlled clinical trial. This project aims to compare postoperative pain control in patients in two treatment arms of rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design: This is a randomized, single blinded, standard of care-controlled clinical trial. All adult patients over eighteen desiring rotator cuff repair will be eligible. Nonnarcotic postoperative pain control regimen described below were chosen based on previous studies in fracture care and joint arthroplasty.

Patients will be consented and recruited. Once participation has been determined and consent obtained, the names of participating patients will be provided to the research pharmacy. Patients will be randomized with a computer-generated table in 2 patient blocks by the research pharmacy. Patients postoperative analgesia will be divided into one of the following 2 treatment arms: 1) A novel nonopioid pain protocol or 2) traditional narcotic pain analgesia

Primary endpoints is reduction in pain as measured by VAS and PROMIS. The endpoints will be collected at each post-operative day using a journal. Moreover, endpoints will be collected at the patient's first post-operative appointment. These appointments are scheduled within one-week of the index procedure.

Statistical Analysis: All continuous data will be analyzed using independent 2-group t tests and reported as means ± standard deviations. Categorical data will be compared between the 2 groups using chi-square tests and reported as counts and percentages. A preliminary test to confirm the quality of variances will be conducted prior to utilizing the t test to confirm the appropriate statistical analysis. Nonparametric equivalents Wilcoxon rank-sum and Fisher exact tests will be used as needed for nonnormal distributions and low variable numbers, respectively. A multivariable regression analysis was performed to assess for potential confounding demographic variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Narcotic Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Post-Operative Non Opioid Pain Protocol

Patients will be administered a post-operative non-opioid pain protocol consisting of:

Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam

Group Type EXPERIMENTAL

Celecoxib

Intervention Type DRUG

Post-Operative Non Opioid Pain Protocol

Ketorolac

Intervention Type DRUG

Post-Operative Non Opioid Pain Protocol

Gabapentin

Intervention Type DRUG

Post-Operative Non Opioid Pain Protocol

Acetaminophen

Intervention Type DRUG

Post-Operative Non Opioid Pain Protocol

Diazepam

Intervention Type DRUG

Post-Operative Non Opioid Pain Protocol

Post-Operative Traditional Pain Protocol

Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325

Group Type ACTIVE_COMPARATOR

Hydrocodone-Acetaminophen

Intervention Type DRUG

Traditionally used narcotic pain protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib

Post-Operative Non Opioid Pain Protocol

Intervention Type DRUG

Hydrocodone-Acetaminophen

Traditionally used narcotic pain protocol

Intervention Type DRUG

Ketorolac

Post-Operative Non Opioid Pain Protocol

Intervention Type DRUG

Gabapentin

Post-Operative Non Opioid Pain Protocol

Intervention Type DRUG

Acetaminophen

Post-Operative Non Opioid Pain Protocol

Intervention Type DRUG

Diazepam

Post-Operative Non Opioid Pain Protocol

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Celebrex Norco Toradol Neurontin Tylenol Valium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All adult patients over age 18 and scheduled for a primary or revision labral surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henry Ford Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Toufic R. Jildeh

Resident Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Toufic R Jildeh, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henry Ford Health System

Detroit, Michigan, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Toufic R Jildeh, MD

Role: CONTACT

Phone: 517-230-8511

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Toufic R Jildeh, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1231914

Identifier Type: -

Identifier Source: org_study_id